Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Huntington Ingalls Industries Inc (HII) Price & Performance

AbCellera Biologics IncTrade
Huntington Ingalls Industries IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Huntington Ingalls Industries Inc — how do they compare? AbCellera Biologics Inc trades at $10.36 (market cap $2.99B), while Huntington Ingalls Industries Inc trades at $326.59 (market cap $12.92B). The key difference: Huntington Ingalls Industries Inc is far larger — about 4.3× AbCellera Biologics Inc's market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLHII
Market Cap
$2.99B$12.92B
Sector
HealthTechnology
52-Week High
$9.76$453.73
52-Week Low
$2.78$265.40
Enterprise Value
$2.58B$15.84B
Dividend Yield
1.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

Huntington Ingalls Industries Inc

HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII